American Journal of Cardiology
Volume 105, Issue 3 , Pages 288-292 , 1 February 2010

Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease

  • Anna Toso, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • Corresponding Author InformationCorresponding author: Tel: 39-0574-434396; fax: 39-0574-434270
    • ,
  • Mauro Maioli, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Mario Leoncini, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Michela Gallopin, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Delio Tedeschi, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Carlo Micheletti, RN

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Concetta Manzone, RN

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Marcello Amato, MD

      Affiliations

    • Division of Nephrology, Misericordia e Dolce Hospital, Prato, Italy
    • ,
  • Francesco Bellandi, MD

      Affiliations

    • Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy

Received 1 July 2009 ,Revised 20 September 2009 ,Accepted 20 September 2009.

References 

  1. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(suppl 6A):5K–13K
  2. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44:1393–1399
  3. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy (A clinical and evidence-based approach). Circulation. 2006;113:1799–1806
  4. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–375
  5. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(suppl 6A):59k–77k
  6. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–386
  7. National Kidney Foundation. K/DOQJ (Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification). Am J Kidney Dis. 2002;39(suppl 1):51–237
  8. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast-associated nephropathy. Arch Intern Med. 2002;162:329–336
  9. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal insufficiency following contrast media administration trial (REMEDIAL) (A randomized comparison of 3 preventive strategies). Circulation. 2007;115:1211–1217
  10. Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599–604
  11. Brar SS, Yuh-Jer Shen A, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate versus sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography. JAMA. 2008;300:1038–1046
  12. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184
  13. Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–2842
  14. Jo S, Yuon T, Koo B, Park J, Kang HJ, Cho YS, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography (The Recovery study). J Am Coll Cardiol. 2006;48:924–930
  15. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62:273–278
  16. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnel MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118:843–849
  17. Patti P, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008;101:279–285
  18. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast-medium–induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—a randomized controlled study. Am Heart J. 2008;155(suppl):499.e1–499.e8
  19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  20. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Elia PP, et al. Standard versus double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206–211
  21. Briguori C, Manganelli F, Scaparto P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298–303
  22. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44:1763–1771
  23. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51:1418–1428
  24. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691–696
  25. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–1454
  26. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384
  27. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149(suppl):473.e1–473.e10
  28. Correia LC, Sposito AC, Lima JC, Magalhães LP, Passos LC, Rocha MS, et al. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non–Q-wave acute myocardial infarction. Am J Cardiol. 2003;92:298–301
  29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention (Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study). Circulation. 2004;110:674–678
  30. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207

PII: S0002-9149(09)02397-2

doi: 10.1016/j.amjcard.2009.09.026

American Journal of Cardiology
Volume 105, Issue 3 , Pages 288-292 , 1 February 2010

Article Tools

* Image Usage & Resolution